How we choose factor VIII to treat hemophilia.

@article{Mannucci2012HowWC,
  title={How we choose factor VIII to treat hemophilia.},
  author={P. Mannucci and M. Mancuso and E. Santagostino},
  journal={Blood},
  year={2012},
  volume={119 18},
  pages={
          4108-14
        }
}
  • P. Mannucci, M. Mancuso, E. Santagostino
  • Published 2012
  • Medicine
  • Blood
    • In high-income countries, the large availability of coagulation factors for replacement therapy of patients with hemophilia A has raised the life expectancy of these lifelong bleeders to that of males from the general population. The practicing clinician is offered a multitude of choices among several commercial brands of factor VIII extracted from human plasma or engineered from mammalian cell cultures by means of recombinant DNA technology. This article has the goal to offer our opinions on… CONTINUE READING
    View on PubMed
    ashpublications.org
    60 Citations
    Highly Influencial Citations
    2
    Background Citations
    16
    60 Citations
    Citation Type

    Citation Type

    Recommendations for factor VIII product source to treat patients with haemophilia A.
    • 3
    The increased demand for plasma-derived factor VIII in Italy.
    • 5
    Emerging drugs for the treatment of hemophilia A and B
    • 7
    Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A
    • 12
    Factor VIII products in haemophilia A: one size fits all?
    • 13
    • PDF
    The inhibitors – a challenge for the management of patients with hereditary haemophilia A
    • R. Mihaila
    • Medicine
    • Romanian journal of internal medicine = Revue roumaine de medecine interne
    • 2018
    • PDF
    The history of hemophilia.
    • 19
    2017 Clinical trials update: Innovations in hemophilia therapy
    • 36
    The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A.
    • B. Kevane, N. O'Connell
    • Medicine
    • Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
    • 2018
    • 2
    Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management
    • P. Mannucci
    • Medicine
    • Haemophilia : the official journal of the World Federation of Hemophilia
    • 2013
    • 10

    References

    SHOWING 1-10 OF 75 REFERENCES
    Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.
    • P. Mannucci
    • Medicine
    • Blood transfusion = Trasfusione del sangue
    • 2010
    • 30
    Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
    • 195
    Role of von Willebrand factor in immune tolerance induction
    • C. Ettingshausen, W. Kreuz
    • Medicine
    • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
    • 2005
    • 70
    Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
    • 108
    • PDF
    Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.
    • 78
    Back to the future: a recent history of haemophilia treatment
    • P. Mannucci
    • Medicine
    • Haemophilia : the official journal of the World Federation of Hemophilia
    • 2008
    • 151
    Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
    • 53
    Hemophilia treatment in developing countries: products and protocols.
    • 26
    French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance.
    • 89
    Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
    • 44